Apotea AB (SE:APOTEA)
:APOTEA
Want to see SE:APOTEA full AI Analyst Report?
Top Page
Apotea AB
(APOTEA)
Select Model
Select Model
Rating:63Neutral
Price Target:
kr77.00
▲(15.79% Upside)
Action:Reiterated
Date:06/02/26
The score is led by improving profitability and a much stronger balance sheet, supported by positive (though uneven) cash generation. Offsetting this, technicals are mixed with the stock below key short/long-term averages, and valuation is stretched (high P/E with a low yield).
Positive Factors
Improving profitability
Steady gross margins (~26–27%) combined with a marked net margin improvement from ~0.4% to ~3.2% signal durable operational gains. This indicates sustainable pricing power and better cost control, supporting ongoing profit resilience as the business scales over the medium term.
Negative Factors
Moderating revenue momentum
Revenue growth stepped down from 2024 and TTM growth is lower versus the prior year, reducing the pace at which scale economies and fixed-cost absorption can improve margins. Slower top-line expansion may force greater reliance on cost measures to sustain profit gains.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving profitability
Steady gross margins (~26–27%) combined with a marked net margin improvement from ~0.4% to ~3.2% signal durable operational gains. This indicates sustainable pricing power and better cost control, supporting ongoing profit resilience as the business scales over the medium term.
Read all positive factors
Apotea AB (APOTEA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr7.98B
Dividend YieldN/A
Average Volume (3M)136.78K
Price to Earnings (P/E)45.8
Beta (1Y)0.43
Revenue Growth9.07%
EPS Growth-96.09%
CountrySE
EmployeesN/A
SectorConsumer Defensive
Sector Strength42
IndustryFood & Drug Retailing
Share Statistics
EPS (TTM)1.67
Shares Outstanding104,070,970
10 Day Avg. Volume129,131
30 Day Avg. Volume136,777
Financial Highlights & Ratios
PEG Ratio7.97
Price to Book (P/B)11.37
Price to Sales (P/S)1.33
P/FCF Ratio81.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.48
Revenue Forecast (FY)kr8.08B
Apotea AB Business Overview & Revenue Model
Company Description
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, ha...
How the Company Makes Money
Apotea makes money primarily by retailing products through its online storefront and earning revenue on each order. Its core revenue streams include: (1) sales of prescription medicines, where revenue is generated from dispensing and fulfilling pr...
Apotea AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.81B | 7.20B | 6.54B | 5.45B | 4.88B | 504.79M |
| Gross Profit | 1.56B | 1.94B | 1.79B | 1.45B | 1.27B | 83.03M |
| EBITDA | 378.24M | 464.10M | 399.60M | 226.00M | 104.80M | 17.74M |
| Net Income | 174.12M | 228.70M | 214.90M | 87.00M | 19.90M | 11.56M |
Balance Sheet | ||||||
| Total Assets | 234.43M | 1.98B | 146.49M | 132.18M | 122.30M | 113.40M |
| Cash, Cash Equivalents and Short-Term Investments | 11.05M | 3.31M | 2.46M | 1.89M | 1.78M | 9.01M |
| Total Debt | 31.09M | 331.00M | 21.78M | 25.89M | 332.70M | 15.97M |
| Total Liabilities | 135.14M | 1.12B | 89.25M | 90.14M | 87.64M | 75.80M |
| Stockholders Equity | 97.60M | 844.00M | 55.37M | 39.93M | 327.50M | 37.60M |
Cash Flow | ||||||
| Free Cash Flow | 185.84M | 117.70M | 42.40M | 94.70M | -110.60M | 16.14M |
| Operating Cash Flow | 224.77M | 333.30M | 206.20M | 215.80M | 31.50M | 25.15M |
| Investing Cash Flow | -38.95M | -214.50M | -163.70M | -121.60M | -141.40M | -9.03M |
| Financing Cash Flow | -127.56M | -115.30M | -34.20M | -93.30M | 46.30M | -8.67M |
Apotea AB Peers Comparison
UnderperformOutperform
Sector (62)
SE:APOTEA
Apotea AB
76.70
-19.41
-20.19%
GB:0R6R
Axfood AB
263.07
-5.47
-2.04%
CLOEF
Cloetta AB
5.17
1.60
44.70%
ETTYF
Essity AB
26.97
-0.38
-1.39%
ZNZNF
Zinzino AB
14.66
-5.29
-26.50%
DE:6MA
Ambea AB
12.75
2.83
28.57%
Apotea AB Corporate Events
Apotea Boosts Capital and Employee Ownership With New Class D Share Issue
May 29, 2026
Apotea has completed a directed new share issue of 400,000 Class D shares under its newly established employee D-share programme, following authorisation from its recent Annual General Meeting. The move modestly increases the company’s share...
Apotea AGM Approves Dividend, Confirms Board Line-up and Governance Framework
May 26, 2026
Apotea AB’s Annual General Meeting approved the 2025 income statements and balance sheets and resolved to distribute a dividend of SEK 0.60 per ordinary share, with payment scheduled for early June 2026. The meeting also discharged the board...
Apotea Delivers Higher Revenue and Profit on Stable Margins in Q1 2026
Apr 29, 2026
Apotea AB, a Swedish online pharmacy and health products retailer, continues to expand its e-commerce presence in the national market. The company leverages a digital-first model to deliver pharmaceuticals and wellness products directly to consume...
Apotea Calls 2026 AGM and Details Shareholder Voting Procedures
Apr 17, 2026
Apotea AB has called its shareholders to an annual general meeting scheduled for 26 May 2026 in Stockholm, setting out the formal requirements for participation and registration. The notice outlines identification and notification procedures, incl...
Apotea AB Publishes 2025 Annual and Sustainability Report
Apr 17, 2026
Apotea AB has released its 2025 Annual and Sustainability Report, which consolidates financial statements, a directors’ report, and a detailed sustainability report for the group. The document, originally published in Swedish and also availa...
Apotea to Present Q1 2026 Results in Webcast on 29 April
Apr 7, 2026
Apotea AB will publish its first-quarter 2026 report on 29 April and will host a webcast presentation the same day for investors, analysts, media and other stakeholders. The results for January to March 2026 will be presented in English by CEO P&#...
Apotea refreshes board with new strategic and financial expertise ahead of 2026 AGM
Mar 31, 2026
Apotea’s Nomination Committee has proposed a largely unchanged board ahead of the 2026 annual general meeting, with the re-election of Chair Cecilia Qvist and four other current directors, while nominating finance and IPO specialist Eva Nils...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.